Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effects of Blood Transfusion in Healthy Volunteers

29. januar 2014 oppdatert av: Warren M. Zapol, Massachusetts General Hospital

Effects of Duration of Stored Red Blood Cell Transfusion on Physiological Parameters and Inflammatory Mediators in Healthy Adult Volunteers

The objective of this study is to assess effects of the storage of PRBC on endothelial function, inflammation and platelet activation in healthy volunteers

Studieoversikt

Status

Fullført

Detaljert beskrivelse

The objective of this study is to assess effects of the storage of PRBC on endothelial function, inflammation and platelet activation in healthy volunteers.

The present study consists of two parts. During one phase of the study, 10 healthy human volunteers will donate a unit of blood, which will be leukoreduced and stored in Additive Solutions-1 (AS-1), and then transfused back to the subjects after 2 days of storage at 4º C in the MGH Blood Bank. The other part of the study consists in the collection of a unit of blood from the same volunteers, but which will be transfused back to the same subject after 40 days of storage. There will be a break of 2 week period in between these 2 study phases. The order of these 2 study parts will be randomized.

We hypothesize that old red blood cells stored under conventional conditions may trigger a complex, pro-inflammatory, pro-thrombotic and vasoconstriction response. We will compare the response to PRBC stored for 2 days with the response to PRBC stored for 40 days in the same healthy volunteers. We will monitor/measure the following markers/parameters:

  1. Endothelium-mediated changes in vascular (arterial) tone
  2. Tissue oxygen saturation will be continuously assessed during and after blood transfusion
  3. Hemolysis as quantified by changes in plasma haptoglobin level, plasma free hemoglobin, LDH level, bilirubin level, iron level, ferritin, and transferrin
  4. Changes of plasma and red blood cell levels of circulating nitrate, nitrite, RXNO, RNNO, NO-heme
  5. Concentration of cytokines, such as IL-6, IL-8, IL-10, IL-12, TNF, IFN-γ
  6. Activation of platelets through circulating P-selectin expression on platelets
  7. Activation of inflammatory lipid mediators
  8. Changes in gene expression profiling analyzing RNA microarray of circulating leukocytes

Studietype

Intervensjonell

Registrering (Faktiske)

10

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital (MGH)

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 40 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Have a photo ID
  • Body mass index (BMI) <25 kg/m2 and >18 kg/m2
  • Fasting for 8 hours prior to enrollment in the study (a sip of water or brushing teeth in the morning are allowed)
  • Feel well the day of blood donation
  • Normal physical exam and normal blood test as indicated:
  • WBC 4.5-11.0 th/cmm
  • HGB 12.5-17.5 gm/dl
  • PLT 150-400 th/cumm
  • Plasma Sodium 135-145 mmol/L
  • Plasma Potassium 3.4-4.8 mmol/L
  • Plasma Chloride 98-108 mmol/L
  • Plasma Carbon Dioxide 23.0-31.9 mmol/L
  • Plasma Urea Nitrogen 8-25 mg/dl
  • Plasma Creatinine 0.60-1.50 mg/dl
  • Plasma Glucose 70-110 mg/dl
  • Transaminase-SGPT 10-55 U/L
  • Transaminase-SGOT 10-40 U/L

Exclusion Criteria:

  • Psychiatric disturbances such as anxiety, depression, schizophrenia requiring pharmacological treatment or hospitalization in the last year
  • Systemic disease with or without any functional limitation
  • controlled hypertension
  • controlled diabetes without systemic effects
  • Pregnancy determined by urine pregnancy test, detecting presence of human chorionic gonadotropin (hCG), or less than six weeks postpartum
  • Active smoking. Volunteers may be enrolled if they quit smoking for more than 1 year
  • Excess alcohol use: more than ½ L/day of wine consumption or equivalent
  • Any current use of a medication other than: Over-the-counter oral medications, herbal remedies, nutritional supplements, and oral contraceptives
  • Antibiotic use within 48 hours of blood donation
  • Use of NSAIDS, corticosteroids, aspirin during the past 7 days
  • Dental work within 24 hours prior to the donation
  • Received or donated blood in the last 4 months
  • Have had any forms of cancer with the exceptions of basal cell skin cancer or treatment for in situ cervical cancer
  • Currently enrolled in another research study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Fresh blood auto-transfusion
Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
Eksperimentell: Old blood auto-transfusion
Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Endothelial function
Tidsramme: Baseline
Baseline
Endothelial function
Tidsramme: 10 min after transfusion
10 min after transfusion
Endothelial function
Tidsramme: 1h after transfusion
1h after transfusion
Endothelial function
Tidsramme: 4h after transfusion
4h after transfusion

Sekundære resultatmål

Resultatmål
Tidsramme
Hemolysis
Tidsramme: Baseline
Baseline
NO metabolites
Tidsramme: Baseline
Baseline
Concentration of cytokines
Tidsramme: Baseline
Baseline
Activation of platelets
Tidsramme: Baseline
Baseline
Activation of inflammatory lipid mediators
Tidsramme: Baseline
Baseline
Changes in gene expression
Tidsramme: Baseline
Baseline
Hemolysis
Tidsramme: 10 min after transfusion
10 min after transfusion
NO metabolites
Tidsramme: 10 min after transfusion
10 min after transfusion
Concentration of cytokines
Tidsramme: 10 min after transfusion
10 min after transfusion
Activation of platelets
Tidsramme: 10 min after transfusion
10 min after transfusion
Activation of inflammatory lipid mediators
Tidsramme: 10 min after transfusion
10 min after transfusion
Changes in gene expression
Tidsramme: 10 min after transfusion
10 min after transfusion
Hemolysis
Tidsramme: 1h after transfusion
1h after transfusion
NO metabolites
Tidsramme: 1h after transfusion
1h after transfusion
Concentration of cytokines
Tidsramme: 1h after transfusion
1h after transfusion
Activation of platelets
Tidsramme: 1h after transfusion
1h after transfusion
Activation of inflammatory lipid mediators
Tidsramme: 1h after transfusion
1h after transfusion
Changes in gene expression
Tidsramme: 1h after transfusion
1h after transfusion
Hemolysis
Tidsramme: 2h after transfusion
2h after transfusion
NO metabolites
Tidsramme: 2h after transfusion
2h after transfusion
Concentration of cytokines
Tidsramme: 2h after transfusion
2h after transfusion
Activation of platelets
Tidsramme: 2h after transfusion
2h after transfusion
Activation of inflammatory lipid mediators
Tidsramme: 2h after transfusion
2h after transfusion
Changes in gene expression
Tidsramme: 2h after transfusion
2h after transfusion
Hemolysis
Tidsramme: 4h after transfusion
4h after transfusion
NO metabolites
Tidsramme: 4h after transfusion
4h after transfusion
Concentration of cytokines
Tidsramme: 4h after transfusion
4h after transfusion
Activation of platelets
Tidsramme: 4h after transfusion
4h after transfusion
Activation of inflammatory lipid mediators
Tidsramme: 4h after transfusion
4h after transfusion
Changes in gene expression
Tidsramme: 4h after transfusion
4h after transfusion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Warren M Zapol, MD, Massachusetts General Hospital, DACCPM

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juli 2010

Primær fullføring (Faktiske)

1. november 2010

Studiet fullført (Faktiske)

1. februar 2011

Datoer for studieregistrering

Først innsendt

14. oktober 2010

Først innsendt som oppfylte QC-kriteriene

20. oktober 2010

Først lagt ut (Anslag)

22. oktober 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

30. januar 2014

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. januar 2014

Sist bekreftet

1. januar 2014

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere